Table 1.
Characterization of HIV broadly neutralizing antibodies
| Broadly neutralising antibody |
Envelope subunit |
Epitope | Breadth (%) | Potency (μg/mL) | Development stage |
|---|---|---|---|---|---|
| 4E10 | gp41 | Gp41 membrane-proximal external region | 13 (32) | 3.41 (32) | Phase I/II clinical trial (NCT00219986) |
| 2FS | gp41 | 19(33) | 2.30 (33) | Phase I/II clinical trial (NCT00219986) | |
| 10E8 | gp41 | 72 (35) | 0.35 (35) | In-vivo (rhesus macaque) (62) | |
| b12 | gp120 | CD4 binding site | 10 (32) | 2.82 (32) | In-vivo (rhesus macaque) (105) |
| VRC01 | gp120 | 74 (32) | 0.33 (32) | Phase II clinical trial (NCT02664415) | |
| VRC01-N | gp120 | ||||
| VRC07 | gp120 | 83 (41) | 0.11 (41) | Phase I clinical trial (NCT03015181) | |
| 3BNC117 | gp120 | 77 35) | 0.11 (35) | Phase II clinical trial (NCT02446847) | |
| NIH45-46 | gp120 | 76 (35) | 0.2 (35) | In-vivo (rhesus macaque) (106) | |
| N6 | gp120 | 96 (43) | 0.038 (43) | In vitro (43) | |
| ECD4-Ig | gp120 | 100 (100) | 0.05 (100) | In-vivo (rhesus macaque) (100) | |
| PG9 | gp120 | V1/V2 domain | 54 (32) | 0.23 (32) | Phase I clinical trial (NCT01937455) |
| PGDM1400 | gp120 | 83 (42) | 0.003 (42) | In-vitro (42) | |
| PGT145 | gp120 | 52 (32) | 0.2 (32) | In-vitro (32) | |
| PG16 | gp120 | 59 (35) | 0.15 (35) | In-vitro (35) | |
| 10-1074 | gp120 | V3 domain | 54 (66) | 0.4 (66) | Phase I clinical trial (NCT02824536) |
| PGT121 | gp120 | 57 (32) | 0.03 (32) | Phase I clinical trial (NCT02960581) | |
| PGT 128 | gp120 | 60 (32) | 0.02 (32) | In vivo (rhesus macaque) (107) |
Breadth is the percentage of viruses neutralized at IC50 > 1 μg/mL in a panel of 100–200 pseudoviruses. Potency is the measure by the IC50 (μg/mL) in a panel of 100–200 pseudoviruses.